Agenus Inc. (AGEN) is primarily known for its pipeline cancer immunothearpy product Prophage and its potential to reach market as a treatment for glioma, but recent headlines have been highlighting another of the company's strengths, its vaccine adjuvant, QS-21.

The potential of QS-21 has long been observed, but a run of recent headlines in the vaccine sector have brought new light to vaccine adjuvants, and the renewed spotlight on AGEN coincides with initatied coverage of the company by MLV Capital, who slapped a tag of 'Buy' on the stock with a price target of $2.50.

QS-21 is currently being used in 15 different vaccine candidates, with multiple of those in Phase III, and Agenus stands to receive royalties on any that are approved.

The MLV coverage and positive press about QS-21 have sparked some life in this otherwise forgotten stock, and it's time again to move this one from its accumulation phases back to being one to watch.

Disclosure: Long AGEN.

Add a Comment